Genmab A/S (NASDAQ:GMAB) Shares Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd increased its position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 371.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 73,696 shares of the company's stock after buying an additional 58,048 shares during the period. Y Intercept Hong Kong Ltd's holdings in Genmab A/S were worth $1,538,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in GMAB. Charles Schwab Investment Management Inc. raised its stake in Genmab A/S by 94.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company's stock valued at $636,000 after buying an additional 12,654 shares during the last quarter. HighTower Advisors LLC acquired a new position in Genmab A/S in the 3rd quarter worth about $273,000. Verition Fund Management LLC acquired a new position in shares of Genmab A/S during the 3rd quarter worth approximately $709,000. Natixis Advisors LLC lifted its holdings in Genmab A/S by 29.8% during the third quarter. Natixis Advisors LLC now owns 206,563 shares of the company's stock valued at $5,036,000 after purchasing an additional 47,437 shares in the last quarter. Finally, FMR LLC increased its stake in shares of Genmab A/S by 13.5% during the third quarter. FMR LLC now owns 278,194 shares of the company's stock worth $6,782,000 after purchasing an additional 33,076 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Price Performance

Shares of Genmab A/S stock traded down $0.16 during trading hours on Friday, hitting $22.57. The company had a trading volume of 338,215 shares, compared to its average volume of 853,398. Genmab A/S has a twelve month low of $18.64 and a twelve month high of $31.88. The company has a market cap of $14.94 billion, a P/E ratio of 12.98, a price-to-earnings-growth ratio of 2.65 and a beta of 0.96. The company's 50-day moving average is $20.93 and its two-hundred day moving average is $22.83.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Sell-side analysts expect that Genmab A/S will post 1.45 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Leerink Partners upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a research note on Thursday, February 13th. BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. BMO Capital Markets reaffirmed an "outperform" rating and set a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Sanford C. Bernstein raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, December 20th. Finally, HC Wainwright reissued a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a research report on Thursday, January 23rd. Four research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Genmab A/S has a consensus rating of "Moderate Buy" and a consensus price target of $42.17.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.